DK452289A - Praeparat eller system til behandling af diabetes - Google Patents
Praeparat eller system til behandling af diabetes Download PDFInfo
- Publication number
- DK452289A DK452289A DK452289A DK452289A DK452289A DK 452289 A DK452289 A DK 452289A DK 452289 A DK452289 A DK 452289A DK 452289 A DK452289 A DK 452289A DK 452289 A DK452289 A DK 452289A
- Authority
- DK
- Denmark
- Prior art keywords
- insulin
- function
- liver
- targeted
- encapsulated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/143,180 US4863896A (en) | 1984-05-03 | 1988-01-13 | Diabetic control by combined insulin forms |
| PCT/US1988/001536 WO1989006540A1 (en) | 1988-01-13 | 1988-05-13 | Diabetic control by combined insulin forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK452289D0 DK452289D0 (da) | 1989-09-13 |
| DK452289A true DK452289A (da) | 1989-11-09 |
Family
ID=22502938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK452289A DK452289A (da) | 1988-01-13 | 1989-09-13 | Praeparat eller system til behandling af diabetes |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4863896A (da) |
| EP (1) | EP0358709B1 (da) |
| AT (1) | ATE78169T1 (da) |
| AU (1) | AU622370B2 (da) |
| DE (1) | DE3872878T2 (da) |
| DK (1) | DK452289A (da) |
| FI (1) | FI894376A0 (da) |
| WO (1) | WO1989006540A1 (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420108A (en) * | 1992-09-14 | 1995-05-30 | Shohet; Isaac H. | Method of controlling diabetes mellitus |
| WO1999016425A1 (en) * | 1997-09-30 | 1999-04-08 | The Ohio State University | Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells |
| US7169410B1 (en) * | 1998-05-19 | 2007-01-30 | Sdg, Inc. | Targeted liposomal drug delivery system |
| US6159931A (en) * | 1998-09-29 | 2000-12-12 | The Ohio State University | Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells |
| US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US7196059B2 (en) | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| WO2003105768A2 (en) * | 2002-06-13 | 2003-12-24 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
| US7384914B2 (en) | 2003-01-06 | 2008-06-10 | Emisphere Technologies, Inc. | Night-time oral insulin therapy |
| US20050203001A1 (en) | 2004-03-05 | 2005-09-15 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
| CN102293746A (zh) * | 2003-09-09 | 2011-12-28 | 吉里德科学公司 | 治疗性脂质体 |
| CN101027318B (zh) * | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物，制剂及其用途 |
| EP3391876B1 (en) * | 2005-05-23 | 2021-03-10 | SDG, Inc. | Lipid construct for delivery of insulin to a mammal |
| US20110135725A1 (en) | 2005-05-23 | 2011-06-09 | Sdg, Inc. | Lipid Construct for Delivery of Insulin to a Mammal |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| WO2009050738A2 (en) | 2007-10-16 | 2009-04-23 | Biocon Limited | An orally administerable solid pharmaceutical composition and a process thereof |
| WO2010080976A1 (en) * | 2009-01-09 | 2010-07-15 | Sdg, Inc. (An Ohio Corporation) | Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments |
| WO2010088268A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
| CA2750269A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Crystalline insulin-conjugates |
| US9050370B2 (en) | 2009-01-28 | 2015-06-09 | Smartcells, Inc. | Conjugate based systems for controlled drug delivery |
| AU2010208305A1 (en) | 2009-01-28 | 2011-09-08 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
| WO2010107520A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| CA2754950A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
| JP2013542915A (ja) | 2010-07-28 | 2013-11-28 | スマートセルズ・インコーポレイテツド | 薬物−リガンドコンジュゲート、その合成およびその中間体 |
| CA2806399A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| CA2805902A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinant lectins, binding-site modified lectins and uses thereof |
| CA2924743A1 (en) | 2013-10-04 | 2015-04-09 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| SG11201908052PA (en) | 2017-03-13 | 2019-09-27 | Sdg Inc | Lipid-based nanoparticles with enhanced stability |
| US11077173B2 (en) | 2017-03-13 | 2021-08-03 | Sdg, Inc. | Lipid-based nanoparticles and methods using same |
| JP2022526842A (ja) * | 2019-04-12 | 2022-05-26 | エスディージー インコーポレイテッド | 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4377567A (en) * | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
| US4603044A (en) * | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
-
1988
- 1988-01-13 US US07/143,180 patent/US4863896A/en not_active Expired - Lifetime
- 1988-05-13 WO PCT/US1988/001536 patent/WO1989006540A1/en active IP Right Grant
- 1988-05-13 DE DE8888904864T patent/DE3872878T2/de not_active Expired - Lifetime
- 1988-05-13 AT AT88904864T patent/ATE78169T1/de not_active IP Right Cessation
- 1988-05-13 AU AU17905/88A patent/AU622370B2/en not_active Ceased
- 1988-05-13 EP EP88904864A patent/EP0358709B1/en not_active Expired - Lifetime
-
1989
- 1989-09-13 DK DK452289A patent/DK452289A/da not_active Application Discontinuation
- 1989-09-15 FI FI894376A patent/FI894376A0/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3872878D1 (de) | 1992-08-20 |
| US4863896A (en) | 1989-09-05 |
| EP0358709A1 (en) | 1990-03-21 |
| AU622370B2 (en) | 1992-04-02 |
| WO1989006540A1 (en) | 1989-07-27 |
| DK452289D0 (da) | 1989-09-13 |
| ATE78169T1 (de) | 1992-08-15 |
| AU1790588A (en) | 1989-08-11 |
| EP0358709B1 (en) | 1992-07-15 |
| FI894376A0 (fi) | 1989-09-15 |
| EP0358709A4 (en) | 1990-03-08 |
| DE3872878T2 (de) | 1992-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK452289D0 (da) | Praeparat eller system til behandling af diabetes | |
| DK0527835T3 (da) | Doseringsform til afgivelse af et anti-Parkinsonmiddel | |
| DK0480934T3 (da) | Lægemiddel, der indeholder ephedrin og koffein til behandling af overvægt | |
| DK642587A (da) | Insulinpraeparat | |
| FI880409A0 (fi) | Transdermalt absorberande doseringsenhet foer estradiol och andra estrogena steroider och administrationsfoerfarande. | |
| SE9401406L (sv) | Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma | |
| ATE96308T1 (de) | Dosierform fuer verabreichung in der humanmedizin. | |
| DE59808186D1 (de) | Transdermales therapeutisches system zur abgabe von hormonen | |
| SE8204874D0 (sv) | Farmaceutiska preparat, innefattande humant insulin och humant proinsulin | |
| ES2107511T3 (es) | Procedimiento para la preparacion de un concentrado de factor xi de la coagulacion sanguinea con alta actividad especifica, apropiado para su uso terapeutico. | |
| KR910005858A (ko) | 지방산 요법 | |
| PT651654E (pt) | Utilizacao de um dimero de lisozima para a preparacao de um medicamento para modular os mecanismos natutais de defesa | |
| KR870010871A (ko) | 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 | |
| DK1007085T3 (da) | Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet | |
| SE9101341D0 (sv) | New medicinal use | |
| Kobrine et al. | Further studies on histamine in spinal cord injury and post traumatic hyperemia | |
| GB2019720A (en) | S-adenosyl-L-homocysteine and salts thereof for use in therapy | |
| Vovin et al. | Therapeutic pathomorphosis of affective psychoses during the process of long-term treatment with lithium salts | |
| 徐济民 et al. | ANTIARRHYTHMIC ACTION OF CHANGROLIN ADMINISTERED BY CONTINUOUS INTRAVENOUS INFUSION | |
| 黄涛生 et al. | Changes in Protein Metabolism of Soleus Muscle in Scalded Rats and the Therapeutic Effects of Leucine and Insulin | |
| 施炳培 et al. | THE RADIATION OF THE HE-NE LASER ON ACUPOINTS IN TREATMENT OF INFANTILE CHRONIC DIARRHEA IN 93 CASES | |
| RU94006632A (ru) | Способ лечения неспецифического язвенного колита | |
| ES256653U (es) | Prenda terapeutica perfeccionada | |
| RU96104613A (ru) | Способ лечения больных эндокринной офтальмопатией |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |